NCT04732065 - ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | Biotech Hunter

Enrollment

208

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

July 31, 2027

Conditions

Diffuse Midline Glioma (DMG)GlioblastomaRecurrent EpendymomaRecurrent Malignant Central Nervous System NeoplasmSpinal Cord GliomaWorld Health Organization (WHO) Grade III GliomaCNS TumorCentral Nervous System Tumor

Interventions

DRUG

ONC206

Given orally (PO)

RADIATION

Standard of Care Radiation Therapy

Undergo RT

PROCEDURE

Optional Proton (1H) MR spectroscopy (MRS)

Optional imaging procedure

Trial Locations (5)

8032

RECRUITING

The University Children's Hospital in Zurich, Zurich

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

30322

RECRUITING

Emory University, Atlanta

48109

RECRUITING

University of Michigan, Ann Arbor

94143

RECRUITING

University of California, San Francisco, San Francisco